Home Cart Sign in  
Chemical Structure| 1846570-31-7 Chemical Structure| 1846570-31-7

Structure of CM-272
CAS No.: 1846570-31-7

Chemical Structure| 1846570-31-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CM-272 is a potent, selective and reversible dual small molecule against G9a and DNMTs activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CM-272

CAS No. :1846570-31-7
Formula : C28H38N4O3
M.W : 478.63
SMILES Code : CN1CCC(NC2=CC(C3=CC=C(C)O3)=NC4=CC(OCCCN5CCCC5)=C(OC)C=C24)CC1
MDL No. :MFCD31812316
InChI Key :RLQLKZTYUYIWDB-UHFFFAOYSA-N
Pubchem ID :118607432

Safety of CM-272

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of CM-272

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Healthy donor MSCs co-cultured with MM.1S cells 50 nM 14 days CM-272 partially reversed the effects of MM cells on MSC gene expression mediated by secretory mechanisms and restored osteogenic differentiation capacity. PMC7813865
Bone marrow-derived mesenchymal stromal cells (MSCs) 50 nM 7 days CM-272 restored the expression of hypermethylated Homeobox genes in myeloma MSCs by inhibiting DNMT and G9a methyltransferase activity, promoting osteogenic differentiation. PMC7813865
Healthy fibroblasts (HDFa, HDFn) 5 nM to 100 µM 48 h To evaluate the impact of CM-272 on the viability of healthy fibroblasts, results showed that CM-272 had minimal effects on healthy cells with IC50 values of 23 µM (HDFa) and 28 µM (HDFn). PMC10830081
Liver cancer cell lines (HepG2, HepT1, Hep3B, HUH7) 5 nM to 100 µM 48 h To evaluate the impact of CM-272 on the viability of liver cancer cell lines, results showed that CM-272 significantly reduced cell viability with an IC50 of 6.4 µM. PMC10830081
HB PDX cell lines (PDX214, PDX243, PDX282, PDX295, PDX303, PDX344, PDX364) 5 nM to 100 µM 48 h To evaluate the impact of CM-272 on the viability of HB PDX cell lines, results showed that CM-272 significantly reduced cell viability with an IC50 of 0.7 µM, while having minimal effects on healthy fibroblasts. PMC10830081
OCI-Ly10 DLBCL cells 125-1000 nM 48 h Inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death PMC5458547
CEMO-1 ALL cells 455 nM 48 h Inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death PMC5458547
MV4-11 AML cells 269 nM 48 h Inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death PMC5458547
OCI-AML-2 AML cells 218 nM 48 h Inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death PMC5458547
Lacun3 IC50 = 1.5 μM 48 h To evaluate the effect of CM-272 on cell proliferation, results showed CM-272 reduced proliferation and induced cell death PMC11531574
H23 IC50 = 0.63 μM 48 h To evaluate the effect of CM-272 on cell proliferation, results showed CM-272 reduced proliferation and induced cell death PMC11531574
A549 IC50 = 1.3 μM 48 h To evaluate the effect of CM-272 on cell proliferation, results showed CM-272 reduced proliferation and induced cell death PMC11531574
H358 IC50 = 0.45 μM 48 h To evaluate the effect of CM-272 on cell proliferation, results showed CM-272 reduced proliferation and induced cell death PMC11531574

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice Myeloma model Intraperitoneal injection 5 mg/kg 5 times/week for 4 weeks CM-272 controlled tumor progression and prevented tumor-associated bone loss, demonstrating anti-myeloma activity and bone-anabolic effects in vivo. PMC7813865
Nude mice (nude-Foxn1nu mice) HB PDX model (HB-282) Intraperitoneal injection (i.p.) 5 mg/kg 5 days per week, until day 7 To evaluate the antitumor efficacy of CM-272 in vivo, results showed that CM-272 significantly inhibited tumor growth but caused severe side effects such as dramatic loss and tumor hemorrhage. PMC10830081
BALB/cA Rag2−/−γc−/− mice ALL, AML and DLBCL xenogeneic models Intravenous (i.v.) 2.5 mg/kg Daily, for 4 weeks (ALL and AML) or 8 weeks (DLBCL) Significantly prolongs survival of AML, ALL and DLBCL xenogeneic models PMC5458547
Mice A549 and Lacun3 subcutaneous xenograft models Intraperitoneal injection 5 mg/kg 5 days a week for several weeks To evaluate the effect of CM-272 on tumor volume, results showed CM-272 significantly reduced tumor volume PMC11531574

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.45mL

2.09mL

1.04mL

20.89mL

4.18mL

2.09mL

References

 

Historical Records

Categories